VedaBio, a developer of amplification-free CRISPR diagnostics, announced the extension of its Series A funding round and a strategic partnership with Siemens Healthineers totaling up to $25 million. The collaboration aims to leverage Siemens’ diagnostic expertise to accelerate commercialization of VedaBio’s rapid infectious disease testing platforms targeting decentralized care settings such as urgent care clinics. This investment and alliance position VedaBio to advance impactful CRISPR-based syndromic testing solutions, expanding access and transforming infectious disease diagnostics.